- Home
- MYGN vs WSBC Comparison
MYGN vs WSBC Comparison
Compare MYGN & WSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- WSBC
- Stock Information
- Founded
- MYGN 1991
- WSBC 1870
- Country
- MYGN United States
- WSBC United States
- Employees
- MYGN N/A
- WSBC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- WSBC Major Banks
- Sector
- MYGN Health Care
- WSBC Finance
- Exchange
- MYGN Nasdaq
- WSBC Nasdaq
- Market Cap
- MYGN 2.0B
- WSBC 2.4B
- IPO Year
- MYGN 1995
- WSBC N/A
- Fundamental
- Price
- MYGN $13.69
- WSBC $33.80
- Analyst Decision
- MYGN Hold
- WSBC Buy
- Analyst Count
- MYGN 12
- WSBC 4
- Target Price
- MYGN $23.92
- WSBC $36.75
- AVG Volume (30 Days)
- MYGN 904.0K
- WSBC 370.8K
- Earning Date
- MYGN 11-07-2024
- WSBC 01-21-2025
- Dividend Yield
- MYGN N/A
- WSBC 4.27%
- EPS Growth
- MYGN N/A
- WSBC N/A
- EPS
- MYGN N/A
- WSBC 2.09
- Revenue
- MYGN $823,600,000.00
- WSBC $566,976,000.00
- Revenue This Year
- MYGN $13.82
- WSBC N/A
- Revenue Next Year
- MYGN $4.59
- WSBC $68.55
- P/E Ratio
- MYGN N/A
- WSBC $16.54
- Revenue Growth
- MYGN 12.15
- WSBC N/A
- 52 Week Low
- MYGN $13.81
- WSBC $25.56
- 52 Week High
- MYGN $29.30
- WSBC $37.36
- Technical
- Relative Strength Index (RSI)
- MYGN 26.49
- WSBC 50.26
- Support Level
- MYGN $13.92
- WSBC $34.52
- Resistance Level
- MYGN $15.44
- WSBC $35.54
- Average True Range (ATR)
- MYGN 0.79
- WSBC 0.77
- MACD
- MYGN 0.03
- WSBC -0.24
- Stochastic Oscillator
- MYGN 3.06
- WSBC 19.00
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company that offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. The company has two reportable segments: community banking and trust and investment services. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. Its market service area primarily includes the Rust Belt region of the United States. Commercial real estate accounts for nearly half of the bank's loan portfolio. The bank has historically grown through both organic growth and acquisitions. The bank's primary component of net revenue is net interest income.